Release savings with a carbon neutral alternative to Fostair 100/6 pMDI1-6
Luforbec is an inhaled combination therapy containing beclometasone (100mcg) and formoterol (6mcg) in a pressurised metered dose inhaler (pMDI)5
Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of COPD (FEV1 <50% predicted normal)5
To read more about how carbon neutrality for Luforbec 100/6 pMDI is achieved, click here.
Luforbec 100/6 pMDI offers an NHS List Price saving of 30% vs Fostair 100/6 pMDI4

to release NHS savings
Fostair 100/6 pMDI and Luforbec 100/6 pMDI are both Category C medicines, therefore Luforbec must be prescribed by brand to release savings for the NHS4
If you would like to know more about Luforbec and the savings opportunities available, please get in touch by email to:
UKRespiratory@lupin.com or call on: 01565 751378